Skip to main content

A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

Completed · Not applicable · NCT05443594

Conditions: Persistent Atrial Fibrillation

At a glance

Research payments reported, 2025
$836,351
U.S. investigators named
36
Sites paid
37
Planned or actual enrollment
669

About the trial

Sponsor
Boston Scientific Corporation
Tested
Phase 1: FARAPULSE Ablation System (device), Phase 2: FARAPULSE Ablation System (device)
Dates
Started 2023-02-28; completion 2025-02-11
Results posted
Yes

The objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).

From ClinicalTrials.gov, last updated 2025-12-16. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Boston Scientific Corporation reported $836,351 in research payments for this study in 2025 (140 payments).

Products named: Clinical Trial Product

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.